Transgene Biotek Limited (BOM:526139)
India · Delayed Price · Currency is INR 3.010
+0.100 (3.44%)
At close: Jul 31, 2026
Transgene Biotek Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 0.61 | 2.84 | 0.08 | 0.03 | 0.15 |
Cash & Short-Term Investments | 0.61 | 2.84 | 0.08 | 0.03 | 0.15 |
Cash Growth | -78.62% | 3593.51% | 148.39% | -79.50% | -37.44% |
Accounts Receivable | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Receivables | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 |
Inventory | 0.34 | 0.34 | 0.34 | 0.34 | 0.95 |
Other Current Assets | 9.24 | 9.37 | 10.6 | 9.99 | 5.8 |
Total Current Assets | 10.27 | 12.64 | 11.1 | 10.45 | 6.98 |
Property, Plant & Equipment | 30.93 | 32.85 | 16.71 | 17.57 | 18.47 |
Long-Term Investments | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 |
Other Intangible Assets | 65.38 | 65.45 | 65.52 | 65.6 | 114.18 |
Other Long-Term Assets | -0 | -0 | - | -0 | 1.4 |
Total Assets | 1,437 | 1,441 | 1,423 | 1,424 | 1,471 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 0.68 | 15.93 | 1.96 | 2.29 | 2.03 |
Accrued Expenses | - | 11.99 | - | - | - |
Short-Term Debt | 103.36 | 84.17 | 89.22 | 81.62 | 72.39 |
Other Current Liabilities | 28.52 | 15.28 | 20.24 | 20.76 | 17.65 |
Total Current Liabilities | 132.56 | 127.38 | 111.41 | 104.67 | 92.06 |
Long-Term Debt | 68.01 | 61.03 | 50.8 | 49.5 | 47.69 |
Long-Term Unearned Revenue | - | - | 1.75 | 3.51 | 5.26 |
Other Long-Term Liabilities | 1,152 | 1,152 | 1,152 | 1,152 | 1,152 |
Total Liabilities | 1,353 | 1,341 | 1,316 | 1,310 | 1,297 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 757.7 | 757.7 | 757.7 | 757.7 | 757.7 |
Additional Paid-In Capital | - | 1,388 | 1,388 | 1,388 | 1,388 |
Retained Earnings | - | -2,306 | -2,299 | -2,293 | -2,233 |
Comprehensive Income & Other | -673.93 | 260.49 | 260.49 | 260.49 | 260.49 |
Shareholders' Equity | 83.77 | 100.3 | 107.13 | 113.69 | 173.77 |
Total Liabilities & Equity | 1,437 | 1,441 | 1,423 | 1,424 | 1,471 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 171.37 | 145.2 | 140.01 | 131.13 | 120.08 |
Net Cash (Debt) | -170.76 | -142.36 | -139.93 | -131.09 | -119.93 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -2.25 | -1.88 | -1.85 | -1.73 | -1.58 |
Filing Date Shares Outstanding | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
Total Common Shares Outstanding | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
Working Capital | -122.29 | -114.73 | -100.32 | -94.22 | -85.08 |
Book Value Per Share | 1.11 | 1.32 | 1.41 | 1.50 | 2.29 |
Tangible Book Value | 18.39 | 34.85 | 41.61 | 48.09 | 59.59 |
Tangible Book Value Per Share | 0.24 | 0.46 | 0.55 | 0.63 | 0.79 |
Land | - | 0.66 | 0.66 | 0.66 | 0.66 |
Buildings | - | 34.09 | 34.09 | 34.09 | 34.09 |
Machinery | - | 127.44 | 110.45 | 110.45 | 110.43 |